

SEQ ID NO:11 alignment

<!--StartFragment-->RESULT 3

AEF10443

ID AEF10443 standard; protein; 116 AA.

XX

AC AEF10443;

XX

DT 15-JUN-2007 (revised)

DT 09-MAR-2006 (first entry)

XX

DE Mouse mAb 1A7 heavy chain variable region protein #8.

XX

KW Vaccine; immune stimulation; pharmaceutical; gene therapy;

KW monoclonal antibody; melanoma; cytostatic; neoplasm; glioma; sarcoma;

KW dermatological disease; nervous system tumor; neurological disease;

KW small cell carcinoma; soft tissue sarcoma; heavy chain variable region;

KW 1A7.

XX

OS Mus sp.

XX

PN US2005287148-A1.

XX

PD 29-DEC-2005.

XX

PF 23-MAR-2005; 2005US-00089266.

XX

PR 17-JAN-1995; 95US-00372676.

PR 16-JAN-1996; 96US-00591196.

PR 21-NOV-1996; 96US-00752844.

PR 15-APR-1999; 99US-00293533.

PR 21-MAY-2002; 2002US-00153401.

XX

PA (CHAT/) CHATTERJEE M.

PA (FOON/) FOON K A.

PA (CHAT/) CHATTERJEE S K.

XX

PI Chatterjee M, Foon KA, Chatterjee SK;

XX

DR WPI; 2006-055971/06.

DR PC:NCBI; gi896293.

DR PC:BIND; 77497,77498.

XX

PT New monoclonal antibody 1A7, useful for treating a disease associated

PT with altered GD2 expression, particularly melanoma, neuroblastoma,

PT glioma, soft tissue sarcoma, and small cell carcinoma.

XX

PS Example 2; Fig 3B; 83pp; English.

XX

CC The present invention relates to a monoclonal antibody 1A7. The
 CC monoclonal antibody (mAb) 1A7 is an anti-idiotypic produced by immunizing
 CC with an antibody specific for ganglioside GD2 and identifying a hybridoma
 CC secreting antibody with immunogenic potential in a multi-step screening
 CC process. When administered to an individual, the 1A7 antibody overcomes
 CC immune tolerance and induces an immune response against GD2, which
 CC comprises a combination of anti-GD2 antibody and GD2-specific T cells.
 CC The invention also relates to polynucleotide and polypeptide derivatives
 CC based on 1A7 which includes single chain variable region molecules,
 CC fusion proteins and various pharmaceutical compositions. The antibody,
 CC polynucleotides and vaccines of the invention are useful for treating a
 CC disease associated with altered GD2 expression, particularly melanoma,
 CC neuroblastoma, glioma, soft tissue sarcoma and small cell carcinoma. The
 CC invention is also useful in gene therapy. The present sequence is a mouse

CC mAb 1A7 heavy chain variable region protein.

CC

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed

CC information from BOND.

XX

SQ Sequence 116 AA;

Query Match 100.0%; Score 602; DB 1; Length 116;
Best Local Similarity 100.0%; Pred. No. 6.1e-49;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QESGPGLVAPSQSL SITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGNTDYN SALK 60
|||||

Db 5 QESGPGLVAPSQSL SITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGNTDYN SALK 64

Qy 61 SRLSISKDNSKSQVFLKMNSLHTDDTARYYCARERDYRLDYWGQGTTVTVSS 112
|||||

Db 65 SRLSISKDNSKSQVFLKMNSLHTDDTARYYCARERDYRLDYWGQGTTVTVSS 116

<!--EndFragment-->